In this video, J. Curtis Nickel, MD, discusses the unmet need for a preventive treatment for patients with recurrent urinary tract infections (UTIs). At the 2021 AUA Annual Meeting, Nickel shared results from the groundbreaking study, "“A novel sublingual vaccine will dramatically alter the clinical management of recurrent urinary tract infections in women.”
Nickel is a professor of the department of urology at Queen’s University and urologist at Kingston and Hotel Dieu General Hospitals, Kingston, Ontario, Canada.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.